THE EFFECT OF MELATONIN ON THE SERUM LEVEL OF INTERLEUKIN 31 IN HERPESVIRUS SKIN DISEASES ON THE BACKGROUND OF HIV.

The immune system of the skin is the first line of defense against various infections, on the other hand, its strategic location as a key barrier between external and internal environment makes the skin an important tool for maintaining homeostasis, so dermatological lesions are often a manifestation of various pathological conditions. Thus, herpesvirus skin diseases, which are the result of reactivation of a latent infection and occur against the background of human immunodeficiency, may be the first manifestation of HIV. Active study of melatonin in recent years in the dermatological field is associated with interest in its biological action, which extends to the skin due to the melatoninergic system, and promising prospects for the development of new treatments. The aim of this study was to investigate the effect of melatonin on the serum levels of interleukin 31 in herpesvirus skin diseases on the background of HIV. The current study selected 40 HIV patients who had an acute herpesvirus infection caused by HSV-1, HSV-2, VZV, EBV, and HHV-8 were selected. Patients were divided into two groups: group I consisted of patients receiving antiretroviral therapy, valaciclovir in standard therapeutic doses and melatonin as immunomodulatory therapy. Patients in the melatonin group received two melatonin tablet, 3 mg for 14 days, 6 mg daily (two doses of 3 mg). Group II included patients who received antiretroviral therapy in combination with valaciclovir. Serum levels of IL-31 were measured before and after 14 days of therapeutic intervention. The mean serum level of IL-31 was significantly lower in the melatonin group (p˂0.05). Also, in both groups, serum levels of IL-31 showed a significant increase compared to the indicator of the norm. The results of this study showed that melatonin administration could modify inflammatory cytokines secretion such as IL-31. Given the low toxicity of melatonin and its ability to reduce side effects and increase the efficiency of therapeutic agents, its use may be important and significant in combined therapy in combination with highly active antiretroviral therapy.

[CLINICAL AND IMMUNOLOGICAL FEATURES OF HERPESVIRUS DISEASES ON THE BACKGROUND OF HIV].

Herpesvirus infections (HI) are the most common HIV-associated diseases. Due to the development of the HIV pandemic, the incidence of HI against the background of HIV infection is steadily increasing, and the implantation of HAART makes certain changes in the course of diseases of this category. The aim of the study was to compare clinical and immunological data in different forms of HI in HIV-positive patients and in patients with normal immune status. From March, 2019 to April 2021, 59 HIV-positive and 60 HIV-negative patients were included in the study. The study used clinical and laboratory methods: ELISA, PCR (HIV RNA, HSV-1, HSV-2, VZV, EBV, CMV, HHV-8), immunological studies (CD3 +, CD4 +, CD8 +, CD4 +/CD8 +, CD20 +). The data were statistically processed using the IBM SPSS Statistics statistical package. The clinical features of herpesvirus skin diseases associated with HIV is closely related to the immune status. The spectrum of clinical manifestations and the incidence of skin and mucous membrane diseases in HIV-infected people are influenced by the severity of immunodeficiency and the systemic use of antiretroviral drugs. The severity of manifestations correlates with the level of CD4 + cells: with a value below 349 cells/µl, an atypical course was observed, and with a value of less than 200 cells/µl, a generalized infectious process.